MRNA Moderna Inc
Company Analysis
Latest News
🟢 Moderna is trading 5.7% up today after in-line August inflation data
Moderna is trading at $144.39 (+5.69%) as broad U.S. markets rally after August inflation matched expectations. - Broad market rally followed 3.4% August CPI,...
Moderna wins UK approval for Spikevax, securing 2026/27 NHS supply deal
The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized Moderna’s updated Spikevax vaccine. This version targets the circulating...
🔴 Moderna is trading 4.75% down today after Rothschild Redburn downgraded shares to Sell
Moderna is trading 4.75% down at $141.79 after Rothschild & Co. Redburn downgraded the shares to Sell from Neutral and raised its price target to $81 from $40,...
🟢 Moderna is trading 4.12% up in pre-market with no fresh company-specific catalyst identified
Moderna is trading 4.12% up now at $155.00 in pre-market, with no fresh company-specific announcement clearly explaining the move. - It is based on the...
🔴 Moderna is trading 4.6% down today after Rothschild & Co. Redburn downgraded to Sell
Moderna is trading 4.6% down now at $143.88 after Rothschild & Co. Redburn downgraded the stock from Neutral to Sell, citing valuation concerns following its...
Moderna Downgraded to 'Sell' by Rothschild & Co. on Valuation Concerns
Rothschild & Co. Redburn downgraded Moderna (NASDAQ:MRNA) from "neutral" to "sell," citing valuation concerns following a significant stock price increase....
🔴 Moderna is trading 4.5% down today after possible profit-taking following melanoma-vaccine surge
Moderna is trading at $147.38 (-4.46%), as investors may be taking profits after the melanoma-vaccine surge. - It is reversing part of its 9.93% gain from...
Moderna Completes $3.0 Billion Offering of 0.00% Convertible Senior Notes Due 2032
Moderna has completed its previously announced private offering of $3.0 billion in aggregate principal amount of 0.00% Convertible Senior Notes due 2032. This...
🟢 Moderna is trading 10% up today after GSK advances mRNA flu vaccine
Moderna is trading at $154.38, up +10.01%, after GSK’s decision to advance an mRNA flu vaccine into Phase III was interpreted as validation of Moderna’s...
Moderna Faces GSK in Key mRNA Patent Hearing in The Hague
Moderna faces a patent infringement hearing today, September 1. The hearing is at the Unified Patent Court's local division in The Hague. GlaxoSmithKline...
🟢 Moderna is trading 4.6% up today with no clear catalyst identified
Moderna is trading 4.6% higher at $146.80, with no clear company-specific catalyst identified for the September 1, 2026 move. - The company announced upcoming...
🟢 Moderna is trading 4.07% up today with no clear company catalyst
Moderna is trading 4.07% up at $143.61, with no new August 31 company announcement clearly explaining the intraday gain. - The stock is recovering after...
🔴 Moderna is trading 6% down today after upsized $2.6 billion note offering raises dilution concerns
Moderna is trading 5.59% down at $134.79 after pricing an upsized $2.6 billion private placement of convertible senior notes due 2032, raising dilution...
Moderna Secures FDA Approval for 2026 Vaccines, Targeting XFG Variant
The U.S. Food and Drug Administration (FDA) approved Moderna’s Spikevax and mNEXSPIKE vaccines on August 27, 2026. These updated formulations target the...
🔴 Moderna is trading 4.6% down today after proposing $2 billion private placement of convertible notes
Moderna is trading 4.6% down now at $142.81 after announcing a proposed $2 billion private placement of convertible senior notes due 2032. - The notes may be...
🔴 Moderna is trading 4.3% down in pre-market as investors take profits after cancer-vaccine rally
Moderna is trading 4.28% down now at $143.25 as investors continue taking profits following the extraordinary cancer-vaccine rally. - Recent coverage...
🔴 Moderna is trading 6.5% down today after profit-taking following its cancer-vaccine rally
Moderna is trading 6.5% down at $148.52 as investors continue taking profits after its extraordinary cancer-vaccine-driven rally. - Recent coverage links the...
🔴 Moderna is trading 5% down today after continued profit-taking following cancer-vaccine rally
Moderna is trading at $151.09 (-4.87%) as investors continue taking profits after its extraordinary recent rally tied to positive Phase 3 cancer-vaccine...
Moderna Upgraded by Wolfe Research, Citing Phase 3 Cancer Vaccine Success
Wolfe Research upgraded Moderna from Underperform to Peer Perform. The rating change follows a successful Phase 3 trial for intismeran, a personalized cancer...
🟢 Moderna is trading 11% up today after positive Phase 3 melanoma-vaccine results
Moderna is trading at $153.71 (+10.67%) as investors extend the sharp repricing after its August 19 Phase 3 melanoma-vaccine results with Merck showed reduced...